Early detection markers in Pancreas Cancer

Cancer Biomarkers

Volumn 1, Issue 2-3, 2005, Pages 157-175

  Farrell, James J ^a   Van Rijnsoever, Marius ^a   Elsaleh, Hany ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarkers; early detection; pancreatic Cancer; pancreatic intraepithelial neoplasia

Indexed keywords

RNA; TUMOR MARKER;

BLOOD; CARCINOMA; CHEMISTRY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; FECES; GENETIC MARKER; GENETICS; HUMAN; PANCREAS JUICE; PANCREAS TUMOR; PATHOLOGY; PRECANCER; REPRODUCIBILITY; REVIEW; RISK FACTOR;

CARCINOMA; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; FECES; GENETIC MARKERS; HUMANS; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; RNA; TUMOR MARKERS, BIOLOGICAL;

EID: 39049183529     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2005-12-304     Document Type: Review

References (195)

1. American Cancer Society, Cancer Facts and Figures 2002, Atlanta, GA, 2002.
2. J.H. Klinkenbijl, J. Jeekel, T. Sahmoud et al., Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group, Ann Surg 230(6) (1999), 776-782, discussion 82-84.
3. C.J. Yeo, R.A. Abrams, L.B. Grochow et al., Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience, Ann Surg 225(5) (1997), 621-33, discussion 33-36.
4. C.J. Yeo, J.L. Lillemoe, K.D. Sitzmann, J.V. Hruban R.H. Goodman and S.N., Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients, Ann Surg 221 (1995), 721-731.
5. T. Tsunoda, Y. Yamamoto, M. Kimoto et al., Staging and treatment for patients with pancreatic cancer. How small is an early pancreatic cancer? J Hepatobiliary Pancreat Surg 5(2) (1998), 128-132.
6. T.A. Sohn, K.A. Campbell, H.A. Pitt et al., Quality of life and long-term survival after surgery for chronic pancreatitis, J Gastrointest Surg 4(4) (2000), 355-364; discussion 64-65.
7. J. Ariyama, M. Suyama, K. Ogawa et al., The detection and prognosis of small pancreatic carcinoma, Int J Pancreatol 7(1-3) (1990), 37-47.
8. D.W. Boyes A.J. Fidler and H.K., The results of treatment of 4389 cases of preclinical cervical squamous carcinoma, J Obstet Gynaecol 77 (1970), 769-780.
9. O.F. Kronborg, C. Olsen, J. Bech, K. Sondergaard and O., Repeated screening for colorectal cancer with fecal occult blood test: a prospective randomized study at Funen. Denmark, Scand J Gastroenterol 24 (1989), 599-606.
10. J.B. Mandel, J.H. Church, T.R. Snover, D.C. Bradley, G.M. Schuman, L.M. et al., Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study, N Engl J Med 328 (1993), 1365-1371.
11. S.M. Sommers, S.A.Warre and S., Pancreatic duct hyperplasia and cancer, Arch Pathol 27 (1954), 629-640.
12. R.H. Hruban, K. Takaori, D.S. Klimstra et al., An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms, Am J Surg Pathol 28(8) (2004), 977-987.
13. C. Rosty, J. Geradts, N. Sato et al., p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis, Am J Surg Pathol 27(12) (2003), 1495-1501.
14. J.D. Day, J.A. Yeo, C. Lai-Goldman, M. Anderson, S.M. Goodman and S.N., Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms, Hum Pathol 27 (1996), 119-124.
15. C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim and M. Perucho, Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes, Cell 53(4) (1988), 549-554.
16. C. Caldas, S.A. Hahn, R.H. Hruban, M.S. Redston, C.J. Yeo and S.E. Kern, Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia, Cancer Res 54(13) (1994), 3568-3573.
17. R.H. Hruban, A.D. van Mansfeld, G.J. Offerhaus et al., Kras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization, Am J Pathol 143(2) (1993), 545-554.
18. H.E. Mulcahy, J. Lyautey, C. Lederrey et al., A prospective study of K-ras mutations in the plasma of pancreatic cancer patients, Clin Cancer Res 4(2) (1998), 271-275.
19. T. Yamada, S. Nakamori, H. Ohzato et al., Detection of Kras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features, Clin Cancer Res 4(6) (1998), 1527-1532.
20. M. Lohr, P. Maisonneuve and A.B. Lowenfels, K-Ras mutations and benign pancreatic disease, Int J Pancreatol 27(2) (2000), 93-103.
21. T. Tabata, T. Fujimori, S. Maeda, M. Yamamoto and Y. Saitoh, The role of Ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis, Int J Pancreatol 14(3) (1993), 237-244.
22. A. Maitra, N.V. Adsay, P. Argani et al., Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray, Mod Pathol 16(9) (2003), 902-912.
23. J.G. Luttges, H. Brocker, V. Schwarte-Waldhoff, I. Henne-Bruns, D. Kloppel and G., Allelic loss is often the first hit in the biallelic inactivation of the p53 and dpc4 genes during pancreatic carcinogenesis, Am J Pathol 158 (2001), 1677-1683.
24. J.A. DiGiuseppe, R.H. Hruban, S.N. Goodman et al., Overexpression of p53 protein in adenocarcinoma of the pancreas, Am J Clin Pathol 101(6) (1994), 684-688.
25. S.K. Apple, J.R. Hecht, D.N. Lewin, S.A. Jahromi, W.W. Grody and R.K. Nieberg, Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis, HumPathol 30(2) (1999), 123-129.
26. S.A. Hahn, M. Schutte, A.T. Hoque et al., DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1, Science 271(5247) (1996), 350-353.
27. RI-D. Wilentz, C.A. Argani, P. McCarthy, D.M. Parsons, J.L. Yeo and C.J., Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression, Cancer Res 60 (2000), 2002-2006.
28. M.H. Goggins, R.H.Kern and S.E., BRCA2is inactivated late in the development of pancreatic intraepithelial neoplasia: Evidence and implications, Am J Pathol 156 (2000), 1767-1771.
29. G. Casey, Y. Yamanaka, H. Friess et al., p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis, Cancer Lett 69(3) (1993), 151-160.
30. J. Lundin, S. Nordling, K. von Boguslawsky, P.J. Roberts and C. Haglund, Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer, Oncology 53(2) (1996), 104-111.
31. M.H. Schutte, R.H. Geradts, J. Maynard, R. Hilgers, W. Rabindran and S.K., Abrogation of the Rb/p16 tumorsuppressive pathway in virtually all pancreatic carcinomas, Cancer Res 57 (1997), 3126-3130.
32. R.G. Wilentz, J. Maynard, R. Offerhaus, G.J. Kang, M. Goggins and M., Inactivation of the p16 (INK4A) tumorsuppressor gene in pancreatic duct lesions: loss of intranuclear expression, Cancer Res 58 (1998), 4740-4744.
33. M.F. Yamano, H. Takagaki, T. Kadowaki, N. Watanabe and H. Shirai, T. Genetic progression and divergence in pancreatic carcinoma, Am J Pathol 156 (2000), 2123-2133.
34. S. Gansauge, F. Gansauge, M. Ramadani et al., Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis, Cancer Res 57(9) (1997), 1634-1637.
35. A.V. Biankin, J.G. Kench, A.L. Morey et al., Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia, Cancer Res 61(24) (2001), 8830-8837.
36. M. Kornmann, T. Ishiwata, J. Itakura, P. Tangvoranuntakul, H.G. Beger and M. Korc, Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival, Oncology 55(4) (1998), 363-369.
37. M. Kornmann, K.D. Danenberg, N. Arber, H.G. Beger, P.V. Danenberg and M. Korc, Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes, Cancer Res 59(14) (1999), 3505-3511.
38. T. Suwa, Y. Hinoda, Y. Makiguchi et al., Increased invasiveness of MUC1 and cDNA-transfected human gastric cancer MKN74 cells, Int J Cancer 76(3) (1998), 377-382.
39. P. Pandey, S. Kharbanda and D. Kufe, Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein, Cancer Res 55(18) (1995), 4000-4003.
40. D. Meerzaman, P.S. Shapiro and K.C. Kim, Involvement of the MAP kinase ERK2 in MUC1 mucin signaling, Am J Physiol Lung Cell Mol Physiol 281(1) (2001), L86-L91.
41. T. Terada, T. Ohta, M. Sasaki, Y. Nakanuma and Y.S. Kim, Expression of MUC apomucins in normal pancreas and pancreatic tumours, J Pathol 180(2) (1996), 160-165.
42. G.E. Kim, H.I. Bae, H.U. Park et al., Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas, Gastroenterology 123(4) (2002), 1052-1060.
43. J. Luttges, G. Zamboni, D. Longnecker and G. Kloppel, The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma, Am J Surg Pathol 25(7) (2001), 942-948.
44. N.V. Adsay, K. Merati, A. Andea et al., The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis, Mod Pathol 15(10) (2002), 1087-1095.
45. American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma, Gastroenterology 117(6) (1999), 1463-1484.
46. M.B. Kimmey, M.P. Bronner, D.R. Byrd and T.A. Brentnall, Screening and surveillance for hereditary pancreatic cancer, Gastrointest Endosc 56(4 Suppl) (2002), S82-S86.
47. A.B. Lowenfels, P. Maisonneuve, E.P. DiMagno et al., Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group, J Natl Cancer Inst 89(6) (1997), 442-446.
48. A.P. Klein, K.A. Brune, G.M. Petersen et al., Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds, Cancer Res 64(7) (2004), 2634-2638.
49. F.M. Giardiello, J.D. Brensinger, A.C. Tersmette et al., Very high risk of cancer in familial Peutz-Jeghers syndrome, Gastroenterology 119(6) (2000), 1447-1453.
50. S.J. Rulyak, A.B. Lowenfels, P. Maisonneuve andT.A. Brentnall, Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds, Gastroenterology 124(5) (2003), 1292-1299.
51. A.B. Lowenfels, P. Maisonneuve, D.C. Whitcomb and M.M. Lerch, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis, Jama 286(2) (2001), 169-170.
52. S.J. Rulyak, M.B. Kimmey, D.L. Veenstra and T.A. Brentnall, Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds, Gastrointest Endosc 57(1) (2003), 23-29.
53. S. Kern, R. Hruban, M.A. Hollingsworth et al., A white paper: the product of a pancreas cancer think tank, Cancer Res 61(12) (2001), 4923-4932.
54. D.T. Silverman, J.A. Dunn, R.N. Hoover et al., Cigarette smoking and pancreas cancer: a case-control study based on direct interviews, J Natl Cancer Inst 86(20) (1994), 1510-1516.
55. L. Gullo, R. Pezzilli and A.M. Morselli-Labate, Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group, N Engl J Med 331(2) (1994), 81-84.
56. W.H. Chow, G. Gridley, O. Nyren et al., Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden, J Natl Cancer Inst 87(12) (1995), 930-931.
57. J. Everhart and D. Wright, Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis, Jama 273(20) (1995), 1605-1609.
58. A.B. Lowenfels, P. Maisonneuve, G. Cavallini et al., Pancreatitis and the risk of pancreatic cancer, International Pancreatitis Study Group. N Engl J Med 328(20) (1993), 1433-1437.
59. J. Luttges, A. Diederichs, M.A. Menke, I. Vogel, B. Kremer and G. Kloppel, Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53, Cancer 88(11) (2000), 2495-504.
60. D.K. Bartsch, M. Sina-Frey, S. Lang et al., CDKN2A germline mutations in familial pancreatic cancer, Ann Surg 236(6) (2002), 730-737.
61. H.F. Vasen, N.A. Gruis, R.R. Frants, P.A. van Der Velden, E.T. Hille and W. Bergman, Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden), Int J Cancer 87(6) (2000), 809-811.
62. S.B. Gruber, M.M. Entius, G.M. Petersen et al., Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome, Cancer Res 58(23) (1998), 5267-5270.
63. G. Lal, G. Liu, B. Schmocker et al., Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations, Cancer Res 60(2) (2000), 409-416.
64. M.S. van der Heijden, C.J. Yeo, R.H. Hruban and S.E. Kern, Fanconi anemia gene mutations in young-onset pancreatic cancer, Cancer Res 63(10) (2003), 2585-2588.
65. H.T. Lynch and R.M. Fusaro, Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome, Pancreas 6(2) (1991), 127-131.
66. W. Bergman and N. Gruis, Familial melanoma and pancreatic cancer, N Engl J Med 334(7) (1996), 471-472.
67. A.M. Goldstein, J.P. Struewing, A. Chidambaram, M.C. Fraser and M.A. Tucker, Genotype-phenotype relationships in US melanoma-prone families with CDKN2A and CDK4 mutations, J Natl Cancer Inst 92(12) (2000), 1006-1010.
68. A.M. Goldstein, M.C. Fraser, J.P. Struewing et al., Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations, N Engl J Med 333(15) (1995), 970-974.
69. M. Mantelli, M. Barile, P. Ciotti et al., High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families, Am J Med Genet 107(3) (2002), 214-21.
70. G.H. Su, R.H. Hruban, R.K. Bansal et al., Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers, Am J Pathol 154(6) (1999), 1835-1840.
71. F.M. Giardiello, S.B. Welsh, S.R. Hamilton et al., Increased risk of cancer in the Peutz-Jeghers syndrome, N Engl J Med 316(24) (1987), 1511-1514.
72. M. Goggins, G.J. Offerhaus,W. Hilgers et al., Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology, Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+, Am J Pathol 152(6) (1998), 1501-1507.
73. R.E. Wilentz, M. Goggins, M. Redston et al., Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity, Am J Pathol 156(5) (2000), 1641-1651.
74. H. Yamamoto, F. Itoh, H. Nakamura et al., Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability, Cancer Res 61(7) (2001), 3139-3144.
75. H. Elsaleh and B. Iacopetta, Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma, Clin Colorectal Cancer 1(2) (2001), 104-109.
76. H. Elsaleh, B. Powell, K. McCaul et al., P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma, Clin Cancer Res 7(5) (2001), 1343-1349.
77. F.U. Weiss, P. Simon, H. Witt et al., SPINK1 mutations and phenotypic expression in patients with pancreatitis associated with trypsinogen mutations, J Med Genet 40(4) (2003), e40-e78.
78. H.Witt, Gene mutations in children with chronic pancreatitis, Pancreatology 1(5) (2001), 432-438.
79. J. Threadgold, W. Greenhalf, I. Ellis et al., The N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of idiopathic chronic pancreatitis but does not cause the disease, Gut 50(5) (2002), 675-681.
80. H. Matsubayashi, N. Fukushima, N. Sato et al., Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and familial pancreatic cancer, Cancer Biol Ther 2(6) (2003), 652-655.
81. S.A. Hahn, B. Greenhalf, I. Ellis et al., BRCA2 germline mutations in familial pancreatic carcinoma, Natl Cancer Inst 95(3) (2003), 214-221.
82. R.H. Hruban, G.M. Petersen, P.K. Ha and S.E.Kern, Genetics of pancreatic cancer. From genes to families, Surg Oncol Clin N Am7(1) (1998), 1-23.
83. H.T. Lynch, M.L. Fitzsimmons, T.C. Smyrk et al., Familial pancreatic cancer: clinicopathologic study of 18 nuclear families, Am J Gastroenterol 85(1) (1990), 54-60.
84. H.T. Lynch, T. Smyrk, S.E. Kern et al., Familial pancreatic cancer: a review, Semin Oncol 23(2) (1996), 251-275.
85. P. Ghadirian, P. Boyle, A. Simard, J. Baillargeon, P. Maisonneuve and C. Perret, Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada, Int J Pancreatol 10(3-4) (1991), 183-196.
86. A.C. Tersmette, G.M. Petersen, G.J. Offerhaus et al., Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer, Clin Cancer Res 7(3) (2001), 738-744.
87. A.P. Klein, T.H. Beaty, J.E. Bailey-Wilson, K.A. Brune, R.H. Hruban and G.M. Petersen, Evidence for a major gene influencing risk of pancreatic cancer, Genet Epidemiol 23(2) (2002), 133-149.
88. H.Tulinius, G.H. Olafsdottir, H. Sigvaldason, L.Tryggvadottir and K. Bjarnadottir, Neoplastic diseases in families of breast cancer patients, J Med Genet 31(8) (1994), 618-621.
89. K.M. Murphy, K.A. Brune, C. Griffin et al., Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17, Cancer Res 62(13) (2002), 3789-3793.
90. M. Goggins, M. Schutte, J. Lu et al., Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas, Cancer Res 56(23) (1996), 5360-5364.
91. H. Ozcelik, B. Schmocker, N. Di Nicola et al., Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients, Nat Genet 16(1) (1997), 17-18.
92. R.A. Abrams, L.B. Grochow, A. Chakravarthy et al., Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels, Int J Radiat Oncol Biol Phys 44(5) (1999), 1039-1046.
93. R.E. Ritts and H.A. Pitt, CA19-9 in pancreatic cancer, Surg Oncol Clin N Am 7(1) (1998), 93-101.
94. M.B. Albert, W.M. Steinberg and J.P. Henry, Elevated serum levels of tumor marker CA19-9 in acute cholangitis, Dig Dis Sci 33(10) (1988), 1223-1225.
95. N. Furuya, S. Kawa, O. Hasebe et al., Comparative study of CA242 and CA19-9 in chronic pancreatitis, Br J Cancer 73(3) (1996), 372-376.
96. P. Legmann, O.Vignaux, B. Dousset et al., Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography, AJR Am J Roentgenol 170(5) (1998), 1315-1322.
97. T.A. Brentnall, M.P. Bronner, D.R. Byrd, R.C. Haggitt and M.B. Kimmey, Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer, Ann Intern Med 131(4) (1999), 247-255.
98. M.I. Canto, M. Goggins, C.J. Yeo et al., Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach, Clin Gastroenterol Hepatol 2(7) (2004), 606-621.
99. W. Schima, R. Fugger, E. Schober et al., Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT, AJR Am J Roentgenol 179(3) (2002), 717-724.
100. F. Obuz, O. Dicle, A. Coker, O. Sagol and S. Karademir, Pancreatic adenocarcinoma: detection and staging with dynamic MR imaging, Eur J Radiol 38(2) (2001), 146-150.
101. M.B. Sheridan, J. Ward, J.A. Guthrie et al., Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis, AJR Am J Roentgenol 173(3) (1999), 583-590.
102. J. Albert, D. Schilling, H. Breer, K.P. Jungius, J.F. Riemann and H.E. Adamek, Mucinous cystadenomas and intraductal papillary mucinous tumors of the pancreas in magnetic resonance cholangiopancreatography, Endoscopy 32(6) (2000), 472-476.
103. D. Delbeke, D.M. Rose, W.C. Chapman et al., Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma, J Nucl Med 40(11) (1999), 1784-1791.
104. C.P. Raut, A.M. Grau, G.A. Staerkel et al., Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer, J Gastrointest Surg 7(1) (2003), 118-126, discussion 27-28.
105. T. Rosch, A. Meining, S. Fruhmorgen et al., A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in biliary strictures, Gastrointest Endosc 55(7) (2002), 870-876.
106. D.A. Bluemke, J.L. Cameron, R.H. Hruban et al., Potentially resectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation, Radiology 197(2) (1995), 381-385.
107. J. Ariyama, M. Suyama, K. Satoh and J. Sai, Imaging of small pancreatic ductal adenocarcinoma, Pancreas 16(3) (1998), 396-401.
108. A.S. Pearson, P. Chiao, L. Zhang et al., The detection of telomerase activity in patients with adenocarcinoma of the pancreas by fine needle aspiration, Int J Oncol 17(2) (2000), 381-385.
109. J.J. Farrell and W.R. Brugge, Intraductal papillary mucinous tumor of the pancreas, Gastrointest Endosc 55(6) (2002), 701-714.
110. N. Fukushima, K.M. Walter, T. Uek et al., Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice, Cancer Biol Ther 2(1) (2003), 78-83.
111. C. Rosty, L. Christa, S. Kuzdzal et al., Identification of hepatocarcinoma-intestine-pancreas/pancreatitisassociated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology, Cancer Res 62(6) (2002), 1868-1875.
112. J. Ariyama, M. Suyama, K. Satoh and K. Wakabayashi, Endoscopic ultrasound and intraductal ultrasound in the diagnosis of small pancreatic tumors, Abdom Imaging 23(4) (1998), 380-386.
113. J.M. Poneros, G.J. Tearney, M. Shiskov et al., Optical coherence tomography of the biliary tree during ERCP, Gastrointest Endosc 55(1) (2002), 84-88.
114. M. Esteller, P.G. Corn, S.B. Baylin and J.G. Herman, A gene hypermethylation profile of human cancer, Cancer Res 61(8) (2001), 3225-3229.
115. T. Ueki, K.M. Walter, H. Skinner, E. Jaffee, R.H. Hruban and M. Goggins, Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived, Oncogene 21(13) (2002), 2114-2117.
116. T. Ueki, M. Toyota, T. Sohn et al., Hypermethylation of multiple genes in pancreatic adenocarcinoma, Cancer Res 60(7) (2000), 1835-1839.
117. N. Fukushima, N. Sato, T. Ueki et al., Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma, Am J Pathol 160(5) (2002), 1573-1581.
118. N. Fukushima, N. Sato, F. Sahin, G.H. Su, R.H. Hruban and M. Goggins, Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms, Br J Cancer 89(2) (2003), 338-343.
119. T. Ueki, M. Toyota, H. Skinner et al., Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma, Cancer Res 61(23) (2001), 8540-8546.
120. N. Sato, N. Fukushima, A. Maitra et al., Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays, Cancer Res 63(13) (2003), 3735-3742.
121. H. Matsubayashi, N. Sato, N. Fukushima et al., Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues, Clin Cancer Res 9(4) (2003), 1446-1452.
122. M. Jansen, N. Fukushima, C. Rosty et al., Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs, Cancer Biol Ther 1(3) (2002), 293-296.
123. N. Sato, N. Fukushima, N. Maehara et al., SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions, Oncogene 22(32) (2003), 5021-5030.
124. N. Sato, A. Maitra, N. Fukushima et al., Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma, Cancer Res 63(14) (2003), 4158-4166.
125. P.O. Brown and D. Botstein, Exploring the new world of the genome with DNA microarrays, Nat Genet 21(1 Suppl) (1999), 33-37.
126. A.A. Alizadeh, M.B. Eisen, R.E. Davis et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403(6769) (2000), 503-511.
127. C.M. Perou, S.S. Jeffrey, M. van de Rijn et al., Distinctive gene expression patterns in human mammary epithelial cells and breast cancers, Proc Natl Acad Sci USA 96(16) (1999), 9212-9217.
128. C.M. Perou, T. Sorlie, M.B. Eisen et al., Molecular portraits of human breast tumours, Nature 406(6797) (2000), 747-752.
129. H. Han, D.J. Bearss, L.W. Browne, R. Calaluce, R.B. Nagle and D.D. Von Hoff, Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray, Cancer Res 62(10) (2002), 2890-2896.
130. C.D. Logsdon, D.M. Simeone, C. Binkley et al., Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer, Cancer Res 63(10) (2003), 2649-2657.
131. H. Hermeking, C. Lengauer, K. Polyak et al., 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression, Mol Cell 1(1) (1997), 3-11.
132. C.A. Iacobuzio-Donahue, A. Maitra, M. Olsen et al., Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays, Am J Pathol 162(4) (2003), 1151-1162.
133. T. Crnogorac-Jurcevic, E. Efthimiou, T. Nielsen et al., Expression profiling of microdissected pancreatic adenocarcinomas, Oncogene 21(29) (2002), 4587-4594.
134. V.E. Velculescu, L. Zhang, B. Vogelstein and K.W. Kinzler, Serial analysis of gene expression, Science 270(5235) (1995), 484-487.
135. B. Ryu, J. Jones, N.J. Blades et al., Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression, Cancer Res 62(3) (2002), 819-826.
136. W. Zhou, L.J. Sokoll, D.J. Bruzek et al., Identifying markers for pancreatic cancer by gene expression analysis, Cancer Epidemiol Biomarkers Prev 7(2) (1998), 109-112.
137. P. Argani, C. Rosty, R.E. Reiter et al., Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma, Cancer Res 61(11) (2001), 4320-4324.
138. P. Argani, C. Iacobuzio-Donahue, B. Ryu et al., Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE), Clin Cancer Res 7(12) (2001), 3862-3868.
139. N.W. Kim, M.A. Piatyszek, K.R. Prowse et al., Specific association of human telomerase activity with immortal cells and cancer, Science 266(5193) (1994), 2011-2015.
140. T. Iwao, E. Hiyama, T. Yokoyama et al., Telomerase activity for the preoperative diagnosis of pancreatic cancer, J Natl Cancer Inst 89(21) (1997), 1621-1623.
141. N. Suehara, K. Mizumoto, M. Kusumoto et al., Telomerase activity detected in pancreatic juice 19 months before a tumor is detected in a patient with pancreatic cancer, Am J Gastroenterol 93(10) (1998), 1967-1971.
142. N. Suehara, K. Mizumoto, M. Tanaka et al., Telomerase activity in pancreatic juice differentiates ductal carcinoma from adenoma and pancreatitis, Clin Cancer Res 3(12 Pt 1) (1997), 2479-2483.
143. K. Seki, T. Suda, Y. Aoyagi et al., Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNAin pancreatic juice with sample qualification, Clin Cancer Res 7(7) (2001), 1976-1981.
144. N.T. van Heek, A.K. Meeker, S.E. Kern et al., Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia, Am J Pathol 161(5) (2002), 1541-1547.
145. N. Suehara, K. Mizumoto, T. Muta et al., Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states, Clin Cancer Res 3(6) (1997), 993-998.
146. E. Hiyama, T. Kodama, K. Shinbara et al., Telomerase activity is detected in pancreatic cancer but not in benign tumors, Cancer Res 57(2) (1997), 326-331.
147. M. Tsutsumi, T. Tsujiuchi, O. Ishikawa et al., Increased telomerase activities in human pancreatic duct adenocarcinomas, Jpn J Cancer Res 88(10) (1997), 971-976.
148. L. Anderson and J. Seilhamer, A comparison of selected mRNAand protein abundances in human liver, Electrophoresis 18(3-4) (1997), 533-537.
149. A. Pandey and M. Mann, Proteomics to study genes and genomes, Nature 405(6788) (2000), 837-846.
150. H. Kuwata, T.T. Yip, M. Tomita and T.W. Hutchens, Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin, Biochim Biophys Acta 1429(1) (1998), 129-141.
151. H.Kuwata, T.T.Yip, C.L.Yip, M. Tomita and T.W. Hutchens, Bactericidal domain of lactoferrin: detection, quantitation, and characterization of lactoferricin in serum by SELDI affinity mass spectrometry, Biochem Biophys Res Commun 245(3) (1998), 764-773.
152. T.Y. Hutchens and TT., New desorption strategies for the mass spectrometric analysis of macromolecules, Rapid Commun Mass Spectrom 7 (1993), 576-580.
153. E. Strauss, New ways to probe the molecules of life, Science 282(5393) (1998), 1406-1407.
154. B. Franzen, T. Hirano, K. Okuzawa et al., Sample preparation of human tumors prior to two-dimensional electrophoresis of proteins, Electrophoresis 16(7) (1995), 1087-1089.
155. K. Okuzawa, B. Franzen, J. Lindholm et al., Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis, Electrophoresis 15(3-4) (1994), 382-390.
156. M.A. Reymond, J.C. Sanchez, C. Schneider et al., Specific sample preparation in colorectal cancer, Electrophoresis 18(3-4) (1997), 622-624.
157. D.S. Young and R.P. Tracy, Clinical applications of twodimensional electrophoresis, J Chromatogr A 698(1-2) (1995), 163-179.
158. S.R. Hingorani, E.F. Petricoin, A. Maitra et al., Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse, Cancer Cell 4(6) (2003), 437-450.
159. J. Koopmann, Z. Zhang, N. White et al., Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry, Clin Cancer Res 10(3) (2004), 860-868.
160. M. Gronborg, J. Bunkenborg, T.Z. Kristiansen et al., Comprehensive Proteomic Analysis of Human Pancreatic Juice, J Proteome Res 3(5) (2004), 1042-1055.
161. S.A. Belinsky, K.J. Nikula, W.A. Palmisano et al., Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis, Proc Natl Acad Sci USA 95(20) (1998), 11891-11896.
162. E. Evron, W.C. Dooley, C.B. Umbricht et al., Detection of breast cancer cells in ductal lavage fluid by methylationspecific PCR, Lancet 357(9265) (2001), 1335-1336.
163. L. Prix, P. Uciechowski, B. Bockmann, M. Giesing and A.J. Schuetz, Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool, Clin Chem 48(3) (2002), 428-435.
164. T. Minamoto, M. Mai and Z. Ronai, K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers-a review, Cancer Detect Prev 24(1) (2000), 1-12.
165. F.A. Wenger, J. Zieren, F.J. Peter, C.A. Jacobi and J.M. Muller, K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis, Langenbecks Arch Surg 384(2) (1999), 181-186.
166. C. Berndt, K. Haubold, F. Wenger et al., K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases, Clin Chem 44(10) (1998), 2103-2107.
167. H. Mulcahy and M.J. Farthing, Diagnosis of pancreaticobiliary malignancy: detection of gene mutations in plasma and stool, Ann Oncol 10(Suppl 4) (1999), 114-117.
168. K.S. Tagore, M.J. Lawson, J.A. Yucaitis et al., Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia, Clin Colorectal Cancer 3(1) (2003), 47-53.
169. J. Koopmann, P. Buckhaults, D.A. Brown et al., Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers, Clin Cancer Res 10(7) (2004), 2386-2392.
170. J. Koopmann, N.S. Fedarko, A. Jain et al., Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma, Cancer Epidemiol Biomarkers Prev 13(3) (2004), 487-491.
171. M. Tada, M. Omata, S. Kawai et al., Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma, Cancer Res 53(11) (1993), 2472-2474.
172. J.L. Van Laethem, P. Vertongen, J. Deviere et al., Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours, Gut 36(5) (1995), 781-787.
173. H. Iguchi, K. Sugano, N. Fukayama et al., Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with pancreatic cancer, Gastroenterology 110(1) (1996), 221-226.
174. R.E.Wilentz, C.H. Chung, P.D. Sturm et al., K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma, Cancer 82(1) (1998), 96-103.
175. H. Kondo, K. Sugano, N. Fukayama et al., Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas, Cancer 79(5) (1997), 900-905.
176. H. Uehara, A. Nakaizumi, M. Baba et al., Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice, Am J Gastroenterol 91(8) (1996), 1616-1621.
177. H. Watanabe, N. Sawabu, Y. Songur et al., Detection of Kras point mutations at codon 12 in pure pancreatic juice for the diagnosis of pancreatic cancer by PCR-RFLP analysis, Pancreas 12(1) (1996), 18-24.
178. H. Watanabe, C. Miyagi, Y. Yamaguchi et al., Detection of K-ras point mutations at codon 12 in pancreatic juice for the diagnosis of pancreatic cancer by hybridization protection assay: a simple method for the determination of the types of point mutation, Jpn J Cancer Res 87(5) (1996), 466-474.
179. H.Watanabe, Y. Yamaguchi, A. Ha et al., Quantitative determination of K-ras mutations in pancreatic juice for diagnosis of pancreatic cancer using hybridization protection assay, Pancreas 17(4) (1998), 341-347.
180. M. Tada, T. Teratani, Y. Komatsu, T. Kawabe, Y. Shiratori and M. Omata, Quantitative analysis of ras gene mutation in pancreatic juice for diagnosis of pancreatic adenocarcinoma, Dig Dis Sci 43(1) (1998), 15-20.
181. N. Furuya, S. Kawa, T. Akamatsu and K. Furihata, Longterm follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice, Gastroenterology 113(2) (1997), 593-598.
182. P.E. Queneau, G.L. Adessi, P. Thibault et al., Early detection of pancreatic cancer in patients with chronic pancreatitis: diagnostic utility of a K-ras point mutation in the pancreatic juice, Am J Gastroenterol 96(3) (2001), 700-704.
183. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S.B. Baylin and J.G. Herman, Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients, Cancer Res 59(1) (1999), 67-70.
184. C. Goessl, H. Krause, M. Muller et al., Fluorescent methylation-specific polymerase chain reaction for DNAbased detection of prostate cancer in bodily fluids, Cancer Res 60(21) (2000), 5941-5945.
185. W.M. Grady, A. Rajput, J.D. Lutterbaugh and S.D. Markowitz, Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer, Cancer Res 61(3) (2001), 900-902.
186. W.A. Palmisano, K.K. Divine, G. Saccomanno et al., Predicting lung cancer by detecting aberrant promoter methylation in sputum, Cancer Res 60(21) (2000), 5954-5958.
187. S.L. Rosas, W. Koch, M.G. da Costa Carvalho et al., Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients, Cancer Res 61(3) (2001), 939-942.
188. K. Mizumoto and M. Tanaka, Genetic diagnosis of pancreatic cancer, J Hepatobiliary Pancreat Surg 9(1) (2002), 39-44.
189. J.M. van Es, M.M. Polak, F.M. van den Berg et al., Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product, J Clin Pathol 48(3) (1995), 218-222.
190. S. Ishimaru, M. Itoh, K. Hanada, A. Tsuchida, T. Iwao and G. Kajiyama, Immunocytochemical detection of p53 protein from pancreatic duct brushings in patients with pancreatic carcinoma, Cancer 77(11) (1996), 2233-2239.
191. T. Iwao, K. Hanada, A. Tsuchida, M. Hirata, N. Eguchi and G. Kajiyama, The establishment of a preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutations, Cancer 82(8) (1998), 1487-1494.
192. S.K. Apple, J.R. Hecht, J.M. Novak, R.K. Nieberg, D.L. Rosenthal andW.W. Grody, Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology smears, Am J Clin Pathol 105(3) (1996), 321-326.
193. M. Tascilar, G.J. Offerhaus, R. Altink et al., Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct, Am J Clin Pathol 116(6) (2001), 831-837.
194. T. van Heek, A.E. Rader, G.J. Offerhaus et al., K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis, Am J Clin Pathol 117(5) (2002), 755-765.
195. D.M. McCarthy, A. Maitra, P. Argani et al., Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases, Appl Immunohistochem Mol Morphol 11(3) (2003), 238-243.